BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2016

Oct 18, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2016-08-03

Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-03	Common Stock	G	400	—	Disposed	378184	Direct
2016-08-04	Common Stock	G	500	—	Disposed	377684	Direct
2016-08-24	Common Stock	G	200	—	Disposed	377484	Direct
2016-10-13	Common Stock	M	53125	$38.59	Acquired	376493	Direct
2016-10-13	Common Stock	S	53125	$86.9753	Disposed	323368	Direct
2016-10-14	Common Stock	M	11000	$17.86	Acquired	334368	Direct
2016-10-14	Common Stock	S	11000	$86.8922	Disposed	323368	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-10-13	Stock Option (right to buy Common Stock)	$38.59	M	53125	Disposed	2018-05-21	Common Stock (53125)	Direct
2016-10-14	Stock Option (right to buy Common Stock)	$17.86	M	11000	Disposed	2018-12-16	Common Stock (11000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	25758	Indirect

Footnotes

F1: On August 3, 2016, the reporting person gifted 400 shares to an educational institution.

F2: On August 4, 2016, the reporting person gifted 500 shares to an educational institution.

F3: On August 24, 2016, the reporting person gifted 200 shares to an educational institution.

F4: Trade made pursuant to a 10b5-1 plan executed on June 9, 2016. Mr. Bienaime's former spouse will receive the net proceeds from the shares sold in this transaction in connection with cash payments owed to her pursuant to a martial separation agreement between her and Mr. Bienaime.

F5: The number of shares reflects transfers made by Mr. Bienaime to his former spouse prior to October 13, 2016, of a total of 54,116 shares pursuant to a marital separation agreement.

F6: The price in column 4 is the weighted average price. The price actually received ranged from $86.15 to $88.23. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F7: The price in column 4 is the weighted average price. The price actually received ranged from $86.41 to $87.78. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F8: Reflects the number of stock options outstanding after the transaction from this specific stock option grant.